Page last updated: 2024-12-07

oxyprothepine decanoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxyprothepine decanoate is an atypical antipsychotic medication that is a long-acting injectable form of oxyprothepine. It is used to treat schizophrenia and other psychotic disorders. Oxyprothepine decanoate is a dopamine and serotonin antagonist, which means that it blocks the effects of these neurotransmitters in the brain. This helps to reduce the symptoms of psychosis, such as hallucinations, delusions, and disorganized thinking. It is generally well-tolerated but can cause side effects such as weight gain, sedation, and movement disorders. The long-acting formulation allows for less frequent injections and improved medication adherence. The long-acting injectable formulation is particularly beneficial for patients who have difficulty adhering to oral medication regimens. The mechanism of action of oxyprothepine decanoate, its efficacy in treating various psychotic disorders, and its long-acting formulation are key areas of ongoing research. '

oxyprothepine decanoate: structure in Negwer, 5th ed, #5882 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID93233
SCHEMBL ID11841252
MeSH IDM0083902

Synonyms (17)

Synonym
einecs 255-592-5
3-(4-(10,11-dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)piperazinyl)propyl decanoate
brn 0905225
oxyprothepine decanoate
oxyprothepin decanoate
decanoic acid, 3-(4-(10,11-dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-1-piperazinyl)propyl ester
decanoic acid, 3-(4-(10,11-dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-1-piperizinyl)propyl ester
3-[4-(3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]propyl decanoate
5-23-02-00470 (beilstein handbook reference)
kfh034qdi8 ,
unii-kfh034qdi8
41931-86-6
oxyprothepin decanoate [who-dd]
SCHEMBL11841252
AKOS030593644
Q27282228
DTXSID70962065
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.89 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (42.86%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]